Jefferies Group’s Neurocrine Biosciences NBIX Stock Holding History

Jefferies Group’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-25,000	Closed	-$2.13M	–	1817
2021 Q4	$2.13M	Hold	25,000	–	–	0.01%	778
2021 Q3	$2.4M	Sell	25,000 -25,000	-50%	-$2.36M	0.02%	702
2021 Q2	$4.87M	Hold	50,000	–	–	0.03%	467
2021 Q1	$4.86M	Buy	50,000 +47,500	+1,900%	+$4.98M	0.04%	392
2020 Q4	$240K	Sell	2,500 -72,500	-97%	-$7M	﹤0.01%	1332
2020 Q3	$7.21M	Sell	75,000 -15,000	-17%	-$1.74M	0.08%	213
2020 Q2	$11K	Buy	90,000 +17,500	+24%	+$1.93M	0.13%	124
2020 Q1	$6.28M	Buy	72,500 +47,500	+190%	+$4.65M	0.07%	248
2019 Q4	$2.69M	Sell	25,000 -123,300	-83%	-$12.9M	0.02%	868
2019 Q3	$13.4M	Buy	148,300 +60,000	+68%	+$5.61M	0.1%	142
2019 Q2	$7.46M	Hold	88,300	–	–	0.05%	311
2019 Q1	$7.78M	Sell	88,300 -37,500	-30%	-$3.13M	0.06%	278
2018 Q4	$8.98M	Buy	125,800 +85,700	+214%	+$8.21M	0.07%	212
2018 Q3	$4.93M	Buy	+40,100	New	+$4.55M	0.03%	533
2016 Q4	–	Sell	-8,600	Closed	-$436K	–	2377
2016 Q3	$436K	Hold	8,600	–	–	﹤0.01%	1671
2016 Q2	$391K	Buy	+8,600	New	+$396K	﹤0.01%	1549

Other funds holding NBIX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Jefferies Group's NBIX Position: Q1 2022 in Review

Jefferies Group sold out of Neurocrine Biosciences (NBIX) in Q1 2022, closing a stake of 19,865 shares — an estimated $1.69M sold.

Jefferies Group first reported a position in NBIX in Q2 2013 and held it in 24 quarters. The position peaked at $13M in Q3 2019. 426 funds tracked by Wall St. Rank hold NBIX as of Q1 2022.

Jefferies Group reported no remaining Neurocrine Biosciences position as of Q1 2022 after selling out during the quarter.
Jefferies Group sold 19,865 Neurocrine Biosciences shares in Q1 2022, an estimated $1.69M.
Jefferies Group first reported a position in Neurocrine Biosciences in Q2 2013 and held it in 24 quarters.
Jefferies Group's Neurocrine Biosciences position peaked at $13M in Q3 2019.
426 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2022.

Based on Jefferies Group's 13F filing for Q1 2022, filed 16 May 2022.